— Early sign of Alzheimer's reversed in lab — One of the earliest known impairments caused by Alzheimer's disease - loss of sense of smell - can be restored by removing a plaque-forming protein in a mouse model of the disease,…
— Parental controls on embryonic development? — When a sperm fertilises an egg, each contributes a set of chromosomes to the resulting embryo, which at these very early stages is called a zygote. Early on, zygotic genes are inert,…
— Newly discovered heart stem cells make muscle and bone — Researchers have identified a new and relatively abundant pool of stem cells in the heart. The findings in the December issue of Cell Stem Cell, a Cell Press publication, show that…
— BUSM researchers develop blood test to detect membranous nephropathy — Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Centre (BMC) has led to the development of a test that can help diagnose…
— New hip implants no better than traditional implants — New hip implants appear to have no advantage over traditional implants, suggests a review of the evidence published on bmj.com today…
— Action needed to improve men's health in Europe — Policies aimed specifically at men are urgently needed to improve the health of Europe's men, say experts on bmj.com today…
— Probiotics reduce infections for patients in intensive care — Traumatic brain injury is associated with a profound suppression of the patient's ability to fight infection. At the same time the patient also often suffers hyper-inflammation, due…
— High blood sugar levels in older women linked to colorectal cancer — Elevated blood sugar levels are associated with an increased risk of colorectal cancer, according to a study led by researchers at Albert Einstein College of Medicine of Yeshiva University.…
— Engineered botulism toxins could have broader role in medicine — The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping…
Tamiflu is more effective at relieving flu symptoms than a combination of tamiflu and relenza
In adults with seasonal influenza A virus infection, the combination of the drugs oseltamivir (tamiflu) and zanamivir (relenza) is less effective than oseltamivir monotherapy and not significantly more effective than zanamivir monotherapy. This key finding comes from a randomised, placebo-controlled trial - in adults presenting with influenza symptoms at general practices throughout France during the seasonal influenza epidemic in 2008-2009 - carried out by Catherine Leport from the University of Paris, France, and colleagues, and reported in this week's PLoS Medicine.
In the past few years oseltamivir and zanamivir have been key drugs for limiting the impact of seasonal influenza both in individuals (by reducing morbidity and mortality) and collectively (by slowing the virus' spread to buy time for vaccine production). In order to inform future influenza pandemic planning, the authors compared the effectiveness of monotherapy with either oseltamivir or zanamivir with the effectiveness of an oseltamivir-zanamivir combination.
Adults who visited their GP with symptoms of an influenza-like illness for less than 36 hours and who had a positive influenza A rapid test were randomised to one of three arms: 1) oral oseltamivir 75 mg twice daily plus zanamivir 10 mg by inhalation twice daily 2) oral oseltamivir 75 mg twice daily plus inhaled placebo or 3) zanamivir 10 mg by inhalation twice daily plus oral placebo. 541 patients were enrolled in the study (192 in group 1; 176 in group 2; and 173 in group 3) of whom 447 were infected with influenza A. Overall the oseltamivir-zanamivir combination was both virologically and clinically less effective than oseltamivir monotherapy. In addition, the clinical effects of the oseltamivir-zanamivir combination on time to resolution of symptoms were not significantly different from that of zanamivir monotherapy.
The authors conclude that their findings call for caution in the use of the oseltamivir-zanamivir combination in treatment of adult outpatients with influenza. Furthermore, as the virological effects of oseltamivir monotherapy over zanamivir monotherapy were superior in this trial, the authors say:
'Oseltamivir should be the recommended primary anti-influenza treatment during influenza seasons with predominant H3N2 viruses naturally susceptible to oseltamivir.'
Or subscribe for our Newsletter, a free e-mail publication. It is published practically every day.
Cardiac patients trial home-based rehabilitation
Health undervalued in reproductive rights debate
Decision support service offers assistance in diagnosing paediatric mental health issues
Researchers clone key sperm-binding proteins